Curated News
By: NewsRamp Editorial Staff
January 02, 2025
Kessler Topaz Meltzer & Check, LLP Files Securities Class Action Lawsuit Against Cassava Sciences, Inc.
Discuss on Reddit
LinkedIn
TelegramTLDR
- Lead plaintiff deadline for securities class action against Cassava Sciences, Inc. is February 10, 2025.
- Investors who suffered Cassava losses during Class Period can seek to be appointed as lead plaintiff through Kessler Topaz Meltzer & Check, LLP.
- Kessler Topaz Meltzer & Check, LLP aims to protect investors from fraud and misconduct, seeking justice for victims of corporate wrongdoing.
- Cassava Sciences, Inc. faces securities class action lawsuit alleging misleading statements about drug's efficacy in treating Alzheimer's disease.
Impact - Why it Matters
This news highlights the importance of transparency and accuracy in pharmaceutical companies' communications about their products. Investors who may have been misled by false statements regarding the effectiveness of Cassava's drug now have the opportunity to seek recourse through legal action.
Summary
The law firm of Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Cassava Sciences, Inc. on behalf of investors who purchased Cassava securities between February 7, 2024, and November 24, 2024. The lawsuit alleges that Cassava made false statements about the effectiveness of its drug, simufilam, in treating Alzheimer's Disease.
Investors who suffered losses may seek to be appointed as lead plaintiff representatives by February 10, 2025. Kessler Topaz Meltzer & Check, LLP encourages affected investors to contact the firm for more information.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Kessler Topaz Meltzer & Check, LLP Files Securities Class Action Lawsuit Against Cassava Sciences, Inc.
